Exelixis Stock Performance
| EXEL Stock | USD 41.36 0.92 2.18% |
Exelixis has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.74, which means possible diversification benefits within a given portfolio. As returns on the market increase, Exelixis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Exelixis is expected to be smaller as well. Exelixis right now shows a risk of 2.19%. Please confirm Exelixis downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to decide if Exelixis will be following its price patterns.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Exelixis may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return (2.18) | Five Day Return (7.35) | Year To Date Return (5.09) | Ten Year Return 809.01 | All Time Return 180.41 |
1 | Acquisition by Johnson David Edward of 27532 shares of Exelixis at 43.122 subject to Rule 16b-3 | 11/25/2025 |
2 | Heres Why Exelixis is a Strong Growth Stock | 12/31/2025 |
3 | Global Retirement Partners LLC Buys 14,852 Shares of Exelixis, Inc. EXEL | 01/09/2026 |
4 | Will Exelixis Beat Estimates Again in Its Next Earnings Report | 01/14/2026 |
5 | Why Exelixis is a Top Momentum Stock for the Long-Term | 01/15/2026 |
6 | Is It Too Late To Consider Exelixis After Strong MultiYear Share Gains | 01/16/2026 |
7 | Exelixis, Inc. Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch | 01/20/2026 |
8 | Exelixis Targets High-Risk Colorectal Cancer As Valuation Looks Undemanding | 01/21/2026 |
9 | Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor | 01/23/2026 |
10 | EXEL vs. EXAS Which Stock Is the Better Value Option | 01/27/2026 |
11 | Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies | 01/28/2026 |
| Begin Period Cash Flow | 263 M | |
| Total Cashflows From Investing Activities | -116.8 M |
Exelixis Relative Risk vs. Return Landscape
If you would invest 3,806 in Exelixis on November 2, 2025 and sell it today you would earn a total of 330.00 from holding Exelixis or generate 8.67% return on investment over 90 days. Exelixis is currently generating 0.1598% in daily expected returns and assumes 2.1893% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Exelixis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Exelixis Target Price Odds to finish over Current Price
The tendency of Exelixis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 41.36 | 90 days | 41.36 | about 75.77 |
Based on a normal probability distribution, the odds of Exelixis to move above the current price in 90 days from now is about 75.77 (This Exelixis probability density function shows the probability of Exelixis Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Exelixis has a beta of 0.74 suggesting as returns on the market go up, Exelixis average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Exelixis will be expected to be much smaller as well. Additionally Exelixis has an alpha of 0.108, implying that it can generate a 0.11 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Exelixis Price Density |
| Price |
Predictive Modules for Exelixis
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Exelixis. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Exelixis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Exelixis Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Exelixis is not an exception. The market had few large corrections towards the Exelixis' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Exelixis, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Exelixis within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 0.74 | |
σ | Overall volatility | 2.06 | |
Ir | Information ratio | 0.04 |
Exelixis Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Exelixis for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Exelixis can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Exelixis is unlikely to experience financial distress in the next 2 years | |
| Exelixis has a strong financial position based on the latest SEC filings | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies |
Exelixis Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Exelixis Stock often depends not only on the future outlook of the current and potential Exelixis' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Exelixis' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 296.1 M | |
| Cash And Short Term Investments | 1.1 B |
Exelixis Fundamentals Growth
Exelixis Stock prices reflect investors' perceptions of the future prospects and financial health of Exelixis, and Exelixis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exelixis Stock performance.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 10.52 B | ||||
| Shares Outstanding | 268.11 M | ||||
| Price To Earning | 48.17 X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 4.97 X | ||||
| Revenue | 2.17 B | ||||
| Gross Profit | 2.21 B | ||||
| EBITDA | 718.75 M | ||||
| Net Income | 521.27 M | ||||
| Cash And Equivalents | 1.53 B | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 190.82 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.08 X | ||||
| Book Value Per Share | 8.06 X | ||||
| Cash Flow From Operations | 699.97 M | ||||
| Earnings Per Share | 2.38 X | ||||
| Market Capitalization | 11.38 B | ||||
| Total Asset | 2.95 B | ||||
| Retained Earnings | (98.65 M) | ||||
| Working Capital | 1.06 B | ||||
| Current Asset | 178.66 M | ||||
| Current Liabilities | 52.25 M | ||||
About Exelixis Performance
By examining Exelixis' fundamental ratios, stakeholders can obtain critical insights into Exelixis' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exelixis is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 87.16 | 82.80 | |
| Return On Tangible Assets | 0.07 | 0.08 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.09 | 0.11 |
Things to note about Exelixis performance evaluation
Checking the ongoing alerts about Exelixis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exelixis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exelixis is unlikely to experience financial distress in the next 2 years | |
| Exelixis has a strong financial position based on the latest SEC filings | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies |
- Analyzing Exelixis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exelixis' stock is overvalued or undervalued compared to its peers.
- Examining Exelixis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exelixis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exelixis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exelixis' stock. These opinions can provide insight into Exelixis' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.725 | Earnings Share 2.38 | Revenue Per Share | Quarterly Revenue Growth 0.108 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.